Azadirachtin B 印楝素 B|cas:106500-25-8|西域试剂

Azadirachtin B 印楝素 B,99.12%

产品编号：Bellancom-133108| CAS NO：106500-25-8| 分子式：C₃₃H₄₂O₁₄| 分子量：662.68

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-133108	￥1500.00	杭州北京（现货）
Bellancom-133108	￥6600.00	杭州北京（现货）
Bellancom-133108	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Azadirachtin B 印楝素 B

产品介绍

Azadirachtin B 是从 Azadirachta indica 种子仁中分离的柠檬苦素。Azadirachtin B 增加碱性磷酸酶 (ALP) 活性并刺激成骨细胞分化。Azadirachtin B 对爱泼斯坦-巴尔病毒早期抗原 (EBV-EA) 具有活性。Azadirachtin B 具有杀虫，杀线虫，抗癌，抗炎，抗病毒和成骨特性。

生物活性

Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the Epstein-Barr virus early antigen (EBV-EA). Azadirachtin B has insecticidal, nematocidal, anticancer, anti-inflammatory, antiviral and osteogenic properties.

体外研究

Azadirachtin B (1 pM-100 µM; 48 hours; Osteoblast cells) treatment shows highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells.
Azadirachtin B increases expression of RunX-2 ∼2.5 fold at 10 nM concentration, ALP expression ∼2.8 fold at 10 nM and 100 pM concentration and OCN expression ∼2.5 folds at 10 nM as compared with control.
Azadirachtin B (Compound 4) exhibits toxicity to the diamondback moth (Plutella xylostella) with an LD₅₀ of 4.85-1.06 µg/g body weight, in 92 h.
Azadirachtin B (compound 21) exhibits moderate or potent inhibitory effects (IC50 value of 384 mol ratio/32 pmol TPA) against the Epstein-Barr virus early antigen (EBV-EA) activation induced by tetradecanoylphorbol-13-acetate (TPA).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Osteoblast cells
Concentration:	1 pM, 100 pM, 10 nM, 1 µM, 100 µM
Incubation Time:	48 hours
Result:	Showed highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells.

体内研究
(In Vivo)

On evaluation of Azadirachtin B (compound 21; oral administration) for its anti-tumor-initiating activity on the two-stage carcinogenesis of mouse skin tumor induced by peroxynitrite (ONOO-; PN) as an initiator and TPA as a promoter, this exhibited marked inhibitory activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (75.45 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5090 mL	7.5451 mL	15.0902 mL
5 mM	0.3018 mL	1.5090 mL	3.0180 mL
10 mM	0.1509 mL	0.7545 mL	1.5090 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.77 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.77 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.77 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。